High grade cervical lesions are caused preferentially by non-European variants of HPVs 16 and 18

High grade cervical lesions are caused preferentially by non-European variants of HPVs 16 and 18
复制标题

DOI:
10.1002/ijc.22481
复制
发表时间:
2007-04-15
影响因子:
6.4
通讯作者:
Villa, Luisa Lina
Villa, Luisa Lina
中科院分区:
医学1区
文献类型:
--
作者:
Sichero, Laura;Ferreira, Silvaneide;Villa, Luisa Lina

文献摘要

被引文献

相似文献

HPV 16和18的宫颈内变异性已被广泛研究,并已被用作病毒传播、持续性和进展至临床相关宫颈病变的流行病学研究中的重要工具。HPV 16和18的非欧洲变体感染与高度鳞状上皮内病变(HSIL)发展的风险增加相关。我们的目的是在巴西进行的一项队列研究中,将两种HPV类型的细胞内分子变异性与持续感染的风险和病变结果相关联。我们通过对LCR片段以及E6和L1基因片段进行测序,仅对HPV-16变异体进行了HPV 16和18型分子变异体的特征分析。对于这两种类型,欧洲变体构成了最普遍和最多样化的群体。HPV-18的持续感染与欧洲变异体的持续检测相关。然而,同时检测HSIL和HPV DNA的风险在携带HPV-16的非欧洲变体的女性中更高。在随访期间检测到的HSIL也观察到相同的趋势。我们的研究证实了非欧洲变异与宫颈肿瘤风险之间的关联,并强调了其地理分布对宫颈癌风险评估的重要性。(c)2007 Wiley-Liss,Inc.
The intratypic variability of HPVs 16 and 18 has been extensively studied and has been used as an important tool in epidemiological studies of viral transmission, persistence and progression to clinically relevant cervical lesions. Infections by non-European variants of HPVs 16 and 18 are associated with an increased risk for the development of high grade squamous intraepithelial lesions (HSIL). Our aim was to correlate the intratypic molecular variability of both HPV types and risk of persistent infection and lesion outcome in a cohort study conducted in Brazil. We characterized molecular variants of HPV types 16 and 18 by sequencing a fragment of the LCR and of the E6 and L1 genes, for HPV-16 variants only. For both types, European variants composed the most prevalent and diverse group. Persistent infections with HPV-18 were associated with continuous detection of European variants. However, risk for simultaneous detection of HSIL and HPV DNA was higher in women harboring non-European variants of HPV-16. The same trend was observed with HSIL detected during follow-up. Our study confirms the association between non-European variants and risk of cervical neoplasia, and highlights the importance of their geographic distribution for cervical cancer risk assessment. (c) 2007 Wiley-Liss, Inc.